A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes

NCT05371730 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed / Refractory Myelodysplastic Syndromes

Interventions

DRUG: NCR300

Sponsor

Nuwacell Biotechnologies Co., Ltd.

Collaborators

[object Object]